A pharmaceutical company in the Northeast has offered 2:1 matching dollars to fund research on a kinase inhibitor they make which our lab believes will be of benefit to patients with alveolar rhabdomyosarcoma. The pharmaceutical company is willing to contribute up to $84,000 to match donations from the community of up to $42,000.
This particular drug (kinase inhibitor) has a good rationale for being important exclusively in the alveolar subtype of rhabdomyosarcoma, and it is rare that we find a partner in industry willing to advance a drug just for alveolar rhabdomyosarcoma to the clinic. The basic science studies we would do (preclinical studies) are the prelude to clinical trial studies that the pharmaceutical company would pay for in full (usually a >$2M investment on their part).
For more information, please email Charles at email@example.com .